Nephrology
Dialysis Patients
0
Pipeline Programs↗
12
Active Trials↗
14
Companies Involved↗
Dialysis Patients is an early-stage landscape with 0 programs across 14 companies. The most active players are Roche, AstraZeneca, Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
148
clinical trials
Completed97 · 66%
Unknown status22 · 15%
Terminated12 · 8%
Recruiting6 · 4%
Not yet recruiting4 · 3%
Withdrawn4 · 3%
Other3 · 2%
Clinical Trials
Trial Activity
148 trials
Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study
Recruiting·—·Phase 2·NCT06929169·80 enrolled
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Active, not recruiting·—·Phase 3·NCT06759077·126 enrolled
The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF
Not yet recruiting·—·Phase 4·NCT07417215·60 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)